These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 20697818)

  • 1. Cardiac effects of 3 months treatment of acromegaly evaluated by magnetic resonance imaging and B-type natriuretic peptides.
    Andreassen M; Faber J; Kjær A; Petersen CL; Kristensen LØ
    Pituitary; 2010 Dec; 13(4):329-36. PubMed ID: 20697818
    [TBL] [Abstract][Full Text] [Related]  

  • 2. N-terminal pro-B-type natriuretic peptide in patients with growth hormone disturbances.
    Andreassen M; Faber J; Vestergaard H; Kistorp C; Kristensen LØ
    Clin Endocrinol (Oxf); 2007 May; 66(5):619-25. PubMed ID: 17492947
    [TBL] [Abstract][Full Text] [Related]  

  • 3. N-terminal pro-brain natriuretic peptide in newly diagnosed acromegaly.
    Arikan S; Bahceci M; Tuzcu A; Gokalp D
    J Endocrinol Invest; 2010 Sep; 33(8):571-5. PubMed ID: 20930495
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cardiac function in growth hormone deficient patients before and after 1 year with replacement therapy: a magnetic resonance imaging study.
    Andreassen M; Faber J; Kjaer A; Petersen CL; Kristensen LØ
    Pituitary; 2011 Mar; 14(1):1-10. PubMed ID: 20730514
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serum markers of cardiovascular risk in patients with acromegaly before and after six months of treatment with octreotide LAR.
    Potter BJ; Beauregard C; Serri O
    Pituitary; 2008; 11(1):49-53. PubMed ID: 17917813
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The growth hormone system and cardiac function in patients with growth hormone disturbances and in the normal population.
    Andreassen M
    Dan Med Bull; 2010 Oct; 57(10):B4162. PubMed ID: 21040685
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of BNP and NT-proBNP in Patients With Heart Failure and Reduced Ejection Fraction.
    Rørth R; Jhund PS; Yilmaz MB; Kristensen SL; Welsh P; Desai AS; Køber L; Prescott MF; Rouleau JL; Solomon SD; Swedberg K; Zile MR; Packer M; McMurray JJV
    Circ Heart Fail; 2020 Feb; 13(2):e006541. PubMed ID: 32065760
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of growth hormone treatment on B-type natriuretic peptide as a marker of heart failure in adults with growth hormone deficiency.
    Wallaschofski H; Saller B; Spilcke-Liss E; Lerch MM; Lohmann T; Eigenthaler M
    Horm Metab Res; 2006 Oct; 38(10):656-61. PubMed ID: 17075774
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of growth hormone treatment on circulating levels of NT-proBNP in patients with ischemic heart failure.
    Karason K; Bobbio E; Polte C; Bollano E; Peterson M; Cittadini A; Caidahl K; Hjalmarson Å; Bengtsson BÅ; Ekelund J; Swedberg K; Isgaard J
    Growth Horm IGF Res; 2020 Dec; 55():101359. PubMed ID: 33099227
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Predictive value of B-type natriuretic peptides in detecting latent left ventricular diastolic dysfunction in beta-thalassemia major.
    Kremastinos DT; Hamodraka E; Parissis J; Tsiapras D; Dima K; Maisel A
    Am Heart J; 2010 Jan; 159(1):68-74. PubMed ID: 20102869
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Active acromegaly is associated with decreased hs-CRP and NT-proBNP serum levels: insights from the Belgian registry of acromegaly.
    Verhelst J; Velkeniers B; Maiter D; Haentjens P; T'Sjoen G; Rietzschel E; Corvilain B; Abrams P; Nobels F; Abs R; Bex M
    Eur J Endocrinol; 2013 Feb; 168(2):177-84. PubMed ID: 23132698
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association between serum n-terminal pro-brain natriuretic peptide concentration and left ventricular dysfunction and extracellular water in continuous ambulatory peritoneal dialysis patients.
    Lee JA; Kim DH; Yoo SJ; Oh DJ; Yu SH; Kang ET
    Perit Dial Int; 2006; 26(3):360-5. PubMed ID: 16722030
    [TBL] [Abstract][Full Text] [Related]  

  • 13. N-terminal pro-brain natriuretic protein levels in takotsubo cardiomyopathy.
    Nguyen TH; Neil CJ; Sverdlov AL; Mahadavan G; Chirkov YY; Kucia AM; Stansborough J; Beltrame JF; Selvanayagam JB; Zeitz CJ; Struthers AD; Frenneaux MP; Horowitz JD
    Am J Cardiol; 2011 Nov; 108(9):1316-21. PubMed ID: 21871590
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Analysis of N-terminal pro-B-type natriuretic peptide and cardiac index in multiple injured patients: a prospective cohort study.
    Kirchhoff C; Leidel BA; Kirchhoff S; Braunstein V; Bogner V; Kreimeier U; Mutschler W; Biberthaler P
    Crit Care; 2008; 12(5):R118. PubMed ID: 18789145
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prohormone brain natriuretic peptide (proBNP), BNP and N-terminal-proBNP circulating levels in chronic hemodialysis patients. Correlation with ventricular function, fluid removal and effect of hemodiafiltration.
    Bargnoux AS; Klouche K; Fareh J; Barazer I; Villard-Saussine S; Dupuy AM; Leray-Moragues H; Giuliani I; Canaud B; Cristol JP
    Clin Chem Lab Med; 2008; 46(7):1019-24. PubMed ID: 18624622
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term pattern of brain natriuretic peptide and N-terminal pro brain natriuretic peptide and its determinants in the general population: contribution of age, gender, and cardiac and extra-cardiac factors.
    Luchner A; Behrens G; Stritzke J; Markus M; Stark K; Peters A; Meisinger C; Leitzmann M; Hense HW; Schunkert H; Heid IM
    Eur J Heart Fail; 2013 Aug; 15(8):859-67. PubMed ID: 23568644
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Decreasing ratio of plasma N-terminal pro-B-type natriuretic peptide and B-type natriuretic peptide according to age.
    Koch AM; Rauh M; Zink S; Singer H
    Acta Paediatr; 2006 Jul; 95(7):805-9. PubMed ID: 16801175
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Natriuretic peptides in chronic kidney disease.
    Tagore R; Ling LH; Yang H; Daw HY; Chan YH; Sethi SK
    Clin J Am Soc Nephrol; 2008 Nov; 3(6):1644-51. PubMed ID: 18632852
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of 12-month treatment with the GH receptor antagonist pegvisomant in patients with acromegaly resistant to long-term, high-dose somatostatin analog treatment: effect on IGF-I levels, tumor mass, hypertension and glucose tolerance.
    Colao A; Pivonello R; Auriemma RS; De Martino MC; Bidlingmaier M; Briganti F; Tortora F; Burman P; Kourides IA; Strasburger CJ; Lombardi G
    Eur J Endocrinol; 2006 Mar; 154(3):467-77. PubMed ID: 16498061
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Direct comparison of three natriuretic peptides for prediction of short- and long-term mortality in patients with community-acquired pneumonia.
    Nowak A; Breidthardt T; Christ-Crain M; Bingisser R; Meune C; Tanglay Y; Heinisch C; Reiter M; Drexler B; Arenja N; Twerenbold R; Stolz D; Tamm M; Müller B; Müller C
    Chest; 2012 Apr; 141(4):974-982. PubMed ID: 22135381
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.